Skip to main content

Relmada Therapeutics, Inc.

RLMD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001553643

In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.

13F holders, Q1 2026

Institutional positions in Relmada Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
103
+27 vs. Q4 2025
Shares held
84.7M
+35.0M (+70.5%) vs. Q4 2025
Total value
$588.8M
+$349.0M (+145.5%) vs. Q4 2025
New holders
37
27 more added
Sold out
10
24 more reduced

2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting RLMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2026: 103 institutions
Q1 2021: 82 institutionsQ2 2021: 85 institutionsQ3 2021: 87 institutionsQ4 2021: 97 institutionsQ1 2022: 113 institutionsQ2 2022: 113 institutionsQ3 2022: 134 institutionsQ4 2022: 110 institutionsQ1 2023: 91 institutionsQ2 2023: 95 institutionsQ3 2023: 88 institutionsQ4 2023: 83 institutionsQ1 2024: 93 institutionsQ2 2024: 79 institutionsQ3 2024: 69 institutionsQ4 2024: 48 institutionsQ1 2025: 44 institutionsQ2 2025: 50 institutionsQ3 2025: 44 institutionsQ4 2025: 78 institutionsQ1 2026: 103 institutionsQ2 2026: 126 institutions
Value heldQ1 2026: $588.8M
Q1 2021: $335.7MQ2 2021: $318.3MQ3 2021: $262.8MQ4 2021: $467.2MQ1 2022: $623.1MQ2 2022: $468.5MQ3 2022: $953.6MQ4 2022: $66.8MQ1 2023: $40.3MQ2 2023: $39.7MQ3 2023: $45.0MQ4 2023: $56.4MQ1 2024: $66.5MQ2 2024: $40.7MQ3 2024: $40.2MQ4 2024: $4.36MQ1 2025: $1.68MQ2 2025: $3.18MQ3 2025: $15.5MQ4 2025: $245.8MQ1 2026: $588.8MQ2 2026: $693.7M
Institutions holding RLMD and their total value by quarter
QuarterHoldersValue
Q2 2026126$693.7M
Q1 2026103$588.8M
Q4 202578$245.8M
Q3 202544$15.5M
Q2 202550$3.18M
Q1 202544$1.68M
Q4 202448$4.36M
Q3 202469$40.2M
Q2 202479$40.7M
Q1 202493$66.5M
Q4 202383$56.4M
Q3 202388$45.0M
Q2 202395$39.7M
Q1 202391$40.3M
Q4 2022110$66.8M
Q3 2022134$953.6M
Q2 2022113$468.5M
Q1 2022113$623.1M
Q4 202197$467.2M
Q3 202187$262.8M
Q2 202185$318.3M
Q1 202182$335.7M

Institutions, Q1 2026

Shares, value and share of portfolio for each institution holding Relmada Therapeutics, Inc.; share changes are against Q4 2025.

Institutions holding RLMD in Q1 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Spruce Street Capital LP6,262,114$43.0M10.34%+2,175,933+53.3%Added
Squadron Capital Management LLC8,474,571$59.0M23.60%+1,774,571+26.5%Added
Janus Henderson Group PLC11,063,862$76.9M0.04%+3,793,862+52.2%Added
Braidwell LP0$00.00%−1,582,257−100.0%Sold out
Two Sigma Advisers, LP0$00.00%−162,200−100.0%Sold out
Seven Fleet Capital Management LP0$00.00%−154,109−100.0%Sold out
ExodusPoint Capital Management, LP0$00.00%−68,883−100.0%Sold out
Citadel Advisors LLC0$00.00%−28,063−100.0%Sold out
Simplex Trading, LLC0$00.00%−18,611−100.0%Sold out
Virtu Financial LLC0$00.00%−17,640−100.0%Sold out
Lighthouse Investment Partners, LLC0$00.00%−15,960−100.0%Sold out
Tortoise Investment Management, LLC0$00.00%−13,909−100.0%Sold out
Front Row Advisors LLC0$00.00%−2−100.0%Sold out
Vanguard Group Inc––––Not filed
Pandora Wealth, Inc.––––Not filed